| Followers | 14 |
| Posts | 1735 |
| Boards Moderated | 0 |
| Alias Born | 01/21/2014 |
Thursday, February 12, 2015 11:47:42 AM
ok I set myself up for negative responses to my question. of course many would want more but remember this is very small company and the employees all wear many hats. you should not compare NWBO to companies that are not equal in market cap or have wall street following/coverage and backing.
People said the same thing about IMUC (I know the differences so spare me the comparisons), but what happened there? You guys act like any naysayers are inexperienced biotech investors, well I can tell you I see a lot more Bio experience in IC Light and Steppen than most of this board.
Anyone that has REALLY invested in small bio knows first hand how risky it is and how much information is required to try and keep your money safe. This company has set what up for success? You are making that conclusion based on little information. The manufacturing capacity we have built? Where is it? We were told ages ago that King had capacity but it seems now that it doesn't! UK and Germany designations? They haven't treated anyone or seen any revenue and the original trial was to end very soon!
Big deal it has a great safety profile, so do 1000 other drugs that lack one important thing, efficacy! Now I believe the treatment works, nowhere near Phase I but it is anything but a forgone conclusion as you would have readers believe!
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
